Boardroom Alpha
Boardroom Alpha
SANA · Additional Proxy Materials (DEFA14A) · Filed April 24, 2026

Sana Biotechnology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 24, 2026
Ticker
SANA
Accession
0001193125-26-174886
Boardroom Alpha · Filing insights

Sana Biotechnology recommends voting FOR the three Class II directors (Bishop, Nelsen, Reicin) and FOR EY’s audit.

About Sana Biotechnology Inc
Market cap
$902M
1Y TSR
+23.6%
3Y TSR
−19.3%
Board grade
C-
Sector
Healthcare
CEO
Steve Harr
Last annual meeting: Jun 4, 2026 · View full Sana Biotechnology Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

SANA BIOTECHNOLOGY, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


LOGO

P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Proxy Materials: Notice of Annual Meeting and Proxy Statement & Annual Report Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 4, 2026 for Stockholders of Record as of April 6, 2026 Sana Biotechnology, Inc. Annual Meeting of Stockholders To order a paper copy of the proxy materials, use one of the following methods by May 25, 2026 at 2:00 PM, Pacific Time. Thursday, June 4, 2026 at 9:00 AM, Pacific Time The Annual Meeting will be a virtual meeting conducted via live audio webcast. Please visit www.proxydocs.com/SANA for registration details. You must register at www.proxydocs.com/SANA in order to attend and participate in the Annual Meeting online. Internet: For a convenient way to view proxy materials, VOTE, and obtain www.investorelections.com/SANA information on how to attend and participate in the Annual Meeting, go to www.proxydocs.com/SANA. To vote your proxy while visiting this website, you will need the Call: 12-digit control number in the box below. 1-866-648-8133 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in Email: the proxy materials before voting. paper@investorelections.com Under United States Securities and Exchange Commission rules, proxy materials do not have * If requesting materials by email, please send a blank email with the to be delivered in paper. Proxy materials can be distributed by making them available on the 12-digit control number (located in the box below) in the subject line. Internet. No other requests, instructions or inquiries should be included in your email. You may request a paper copy of the proxy materials. There is no charge to you for requesting a Your control number copy. In order to receive a paper copy of the proxy materials in time for this year’s meeting, you must request a copy on or before May 25, 2026 at 2:00 PM, Pacific Time, using one of the methods described to the right. Unless requested, you will not otherwise receive a paper copy of the proxy materials. Have the 12-digit control number located in the box above available when registering to attend the Annual Meeting, voting online, and requesting proxy materials using the SEE REVERSE FOR FULL AGENDA methods described above. Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


LOGO

Sana Biotechnology, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE:    FOR each nominee for election for Proposal 1 and FOR Proposal 2. PROPOSAL 1. To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: 1.01 Hans E. Bishop 1.02 Robert Nelsen 1.03 Alise S. Reicin, M.D. 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: Stockholders will also consider and act upon any other matters which may properly come before the Annual Meeting or any adjournment or postponement thereof. The named proxies are authorized to vote in their discretion upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Our Board of Directors is not aware of any other business to be presented to a vote of the stockholders at the Annual Meeting.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Sana Biotechnology Inc (SANA)

Reference

Frequently asked questions

When did Sana Biotechnology Inc file this DEFA14A?
Sana Biotechnology Inc (SANA) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001193125-26-174886.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Sana Biotechnology recommends voting FOR the three Class II directors (Bishop, Nelsen, Reicin) and FOR EY’s audit. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Sana Biotechnology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Sana Biotechnology Inc has filed under CIK 1770121, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer